Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-23

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

NCT05121480

Atopic Dermatitis

COMPLETED PHASE2

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

NCT04668066

Atopic Dermatitis

COMPLETED PHASE1

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

NCT07150845

Atoptic Dermatitis

RECRUITING PHASE2

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

NCT05439941

Atopic Dermatitis

TERMINATED PHASE2

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898

Atopic Dermatitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 1a/1b, first in human, participant and investigator-blind sponsor-unblinded randomized placebo-controlled multiple dose study of EDP1867 in healthy volunteers and participants with moderate atopic dermatitis and, optionally, moderate psoriasis, and/or mild asthma. This study has been designed to investigate the clinical safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis Psoriasis Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 7.5 x 10\^11 cells, capsules, once daily, 14 days total

Group Type EXPERIMENTAL

EDP1867

Intervention Type DRUG

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Placebo

Intervention Type DRUG

Placebo oral capsule

Cohort 2

12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 1.5 x 10\^12 cells, capsules, once daily, 14 days total

Group Type EXPERIMENTAL

EDP1867

Intervention Type DRUG

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Placebo

Intervention Type DRUG

Placebo oral capsule

Cohort 3

24 subjects with moderate atopic dermatitis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days

Group Type EXPERIMENTAL

EDP1867

Intervention Type DRUG

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Placebo

Intervention Type DRUG

Placebo oral capsule

Cohort 4

24 subjects with moderate psoriasis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days

Group Type EXPERIMENTAL

EDP1867

Intervention Type DRUG

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Placebo

Intervention Type DRUG

Placebo oral capsule

Cohort 5

24 subjects with mild asthma; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days

Group Type EXPERIMENTAL

EDP1867

Intervention Type DRUG

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Placebo

Intervention Type DRUG

Placebo oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EDP1867

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention Type DRUG

Placebo

Placebo oral capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years to 65 years.
2. Participant has a body mass index of ≥ 18 kg/m2 to ≤ 35 kg/m2.
3. Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG monitoring at Screening and at Baseline.

4. Participant has moderate atopic dermatitis with a minimum of 5% and a maximum of 40% BSA involvement, and an IGA score of 2 or 3.
5. Participant has had a confirmed diagnosis of atopic dermatitis for at least 6 months.
6. All participants must be using an emollient and should continue to use this once daily (or more, as needed) for at least 14 days prior to randomisation, and must continue this treatment once daily (or more, as needed) throughout the study.

7. Participant has moderate plaque psoriasis with plaque covering BSA of ≥3% and ≤10% and meets both of the following additional criteria:

1. PASI score of ≥6 and ≤15, and
2. PGA score of 2 or 3.
8. Participant has a confirmed diagnosis of plaque psoriasis for at least 6 months.

9. Participant has a diagnosis of stable asthma for at least six months
10. FeNO of ≥40ppb.
11. FEV1 ≥70% of predicted normal.

Exclusion Criteria

1. Participant has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study (non-live vaccines are permitted).
2. Participant requires treatment with an anti-inflammatory drug during the study period.
3. Participant has an active infection (e.g. sepsis, pneumonia, abscess) or has had an infection requiring antibiotic treatment within 6 weeks prior to study intervention administration.
4. Participant has renal or liver impairment
5. Participant has active neoplastic disease or history of neoplastic disease within 5 years of Screening
6. Participant has undergone major surgery within 4 weeks prior to Screening.
7. Any known cardiac abnormality
8. Participant has a known history of human immunodeficiency virus (HIV)
9. Known, active hepatitis A, hepatitis B (HBV), or hepatitis C (HCV) infection
10. Participant with any type of GI tract disease
11. Participants with a history of any serious psychiatric condition; or on therapy for any psychiatric condition
12. The participant has taken any over-the-counter (OTC) or prescription medication, within 14 days prior to baseline (Day -1); or anticipates an inability to abstain from these products for the duration of the study period
13. The participant has a significant history of drug abuse or regular use of illicit drugs or a history of alcohol abuse within 1 year prior to Screening or has tested positive for drugs of abuse or alcohol at Screening or at baseline.
14. The participant has had an acute, clinically significant illness within 30 days prior to the first dose of study intervention.

15. Participant is receiving systemic immunosuppressive or non-biologic atopic dermatitis therapy or has received such therapy within 4 weeks prior to Screening.
16. Participant has received treatment with biologic agents within 12 months prior to first dose.
17. Participant continues to use topical medications, other than emollients, that could affect atopic dermatitis 2 weeks prior to the start of dosing.
18. Participant intends to continue to use sunbeds and/or increase their sun exposure significantly from their normal lifestyle

19. Psoriasis restricted to scalp, palm, and/or soles only.
20. Non-plaque type of psoriasis
21. Participant is receiving systemic immunosuppressive or nonbiologic psoriasis therapy or has received such therapy within 4 weeks prior to Screening
22. Participant has received treatment with biologic agents within 12 months prior to first dose.
23. Participant continues to use topical medications that could affect psoriasis within 2 weeks prior to the start of dosing
24. Participant intends to continue to use sunbeds and/or increase their sun exposure significantly from their normal lifestyle

25. History of life-threatening asthma, or a visit to the emergency department for asthma in the 6 months prior to screening, or exacerbation requiring oral corticosteroids within the previous 3 months.
26. Smoker or nicotine user within the 3 months prior to screening; or a previous smoker with a greater than 10 pack year history.
27. Other significant non-reversible pulmonary disease
28. Use of the following medicines within the specified time-frame prior to screening:

1. Long-acting inhaled β2-agonists: 8 weeks. Note: short-acting inhaled β2-agonists are permitted as required.
2. Anti-IgE therapy: 6 months
3. Inhaled corticosteroids: 8 weeks
4. Oral or Injected corticosteroids: 8 weeks
5. Intranasal or topical steroids: 4 weeks
6. Leukotriene antagonists: 2 weeks
7. Long-acting muscarinic antagonist: 8 weeks
8. Xanthines (excluding caffeine), anticholinergics, cromoglycates: 1 week.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes